ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals announced that underwriters fully exercised their option to purchase additional shares in connection with its initial public offering. The full exercise signals incremental investor demand and increases the capital raised, although no share count or dollar amount was provided. The development is modestly positive for ADARx's post-IPO financing position.